Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.

Breast cancer research and treatment - 1 Jun 2016

Gelsomino Luca, Gu Guowei, Rechoum Yassine, Beyer Amanda R, Pejerrey Sasha M, Tsimelzon Anna, Wang Tao, Huffman Kenneth, Ludlow Andrew, Andò Sebastiano, Fuqua Suzanne A W

Abstract excerpt

The purpose of this study was to address the role of ESR1 hormone-binding mutations in breast cancer. Soft agar anchorage-independent growth assay, Western blot, ERE reporter transactivation assay, proximity ligation assay (PLA), coimmunoprecipitation assay, silencing assay, digital droplet PCR (ddPCR), Kaplan-Meier analysis, and statistical analysis. It is now generally accepted that estrogen receptor (ESR1)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Estrogen Receptor alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to MCF-7 Cells

Share to Receptor, IGF Type 1

Share to Receptors, Estrogen

Share to Receptors, Somatomedin

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 27178332
DOI: 10.1007/s10549-016-3829-5
PMCID: PMC5510243

Genes

ESR1
HBD

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.PMID 27178332Read ↗

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Semantic proximity Read ↗

ESR1 mutations in breast cancerSemantic proximity Read ↗

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.Semantic proximity Read ↗

Estrogen receptor mutations and their role in breast cancer progression.Semantic proximity Read ↗

Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 PatientsSemantic proximity Read ↗

ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.Semantic proximity Read ↗

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.Semantic proximity Read ↗

Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.Semantic proximity Read ↗

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read ↗

Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer.Semantic proximity Read ↗

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Semantic proximity Read ↗

Endocrine therapy resistance: new insights.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.